{"organizations": [], "uuid": "83452d21110a172ca28f0172c1e062c37fa33592", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-vbl-therapeutics-announces-top-lin/brief-vbl-therapeutics-announces-top-line-results-from-pivotal-phase-3-globe-study-in-patients-with-recurrent-glioblastoma-idUSFWN1QQ0AJ", "country": "US", "domain_rank": 408, "title": "BRIEF-VBL Therapeutics Announces Top-Line Results From Pivotal Phase 3 Globe Study In Patients With Recurrent Glioblastoma", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.713, "site_type": "news", "published": "2018-03-08T19:18:00.000+02:00", "replies_count": 0, "uuid": "83452d21110a172ca28f0172c1e062c37fa33592"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-vbl-therapeutics-announces-top-lin/brief-vbl-therapeutics-announces-top-line-results-from-pivotal-phase-3-globe-study-in-patients-with-recurrent-glioblastoma-idUSFWN1QQ0AJ", "ord_in_thread": 0, "title": "BRIEF-VBL Therapeutics Announces Top-Line Results From Pivotal Phase 3 Globe Study In Patients With Recurrent Glioblastoma", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "vascular biogenics ltd", "sentiment": "negative"}, {"name": "glioblastoma", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 8 (Reuters) - Vascular Biogenics Ltd:\n* VBL THERAPEUTICS ANNOUNCES TOP-LINE RESULTS FROM PIVOTAL PHASE 3 GLOBE STUDY IN PATIENTS WITH RECURRENT GLIOBLASTOMA\n* VASCULAR BIOGENICS LTD - ‍STUDY DID NOT MEET ITS PRE-SPECIFIED PRIMARY ENDPOINT OF OVERALL SURVIVAL​\n* VASCULAR BIOGENICS LTD - PHASE 3 GLOBE STUDY DID NOT MEET ITS PRE-SPECIFIED PRIMARY ENDPOINT OF OVERALL SURVIVAL​\n* VASCULAR BIOGENICS LTD - ‍BELIEVE THAT VB-111 MAY STILL HOLD PROMISE FOR OTHER INDICATIONS CO CURRENTLY OR MAY STUDY IN FUTURE​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-08T19:18:00.000+02:00", "crawled": "2018-03-08T13:43:05.018+02:00", "highlightTitle": ""}